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Abstract. Technetium-99m methoxyisobutylisonitrile 
(MIBI), like thallium-201, has recently been introduced 
as a myocardial perfusion agent and is now also show- 
ing very promising results in parathyroid scintigrapy. 
The results of 2°lT1/99n~c-pertechnetate and 99mTc- 
MIBI/99myc-pertechnetate subtraction scintigraphy, ul- 
trasonography and computed tomography are presented 
in a series of 43 patients operated on for hyperparathy- 
roidism. All four imaging modalities were confirmed to 
he reliable, scintigraphy being the most accurate. Sen- 
sitivities ranged from 81% to 95%, that of 99nrFc-MIBI 
being the highest. Moreover this tracer, which has more 
favourable physical and also biochemical properties, 
yielded images of superior quality. This allowed local- 
ization of the lesion by visual inspection only in as 
many as 86% of the patients with positive 99'rrFc- 
99 MIBI/ ~Tc-pertechnetate subtraction scintigraphy. We 
believe that the higher sensitivity, superior image qu- 
ality and lower cost of 99rrrFc-MIBI imaging will make 
99~Fc-MIBI the new radiopharmaceutical of choice for 
parathyroid scintigraphy (when one takes into account 
the stability of labelling with large activities it is 
possible to perform three or four cardiac studies to- 
gether with one parathyroid scintigraphic examination 
using one lyophililzed vial). 
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Introduction 
Thallium-201/technetium-99m pertechnetate (99'VrFCO4-) 
subtraction scintigraphy, first introduced in the early 
1980s [1], is one of the most reliable imaging modalities 
for localization of parathyroid enlargement. Neverthe- 
less, Z°lT1 cannot be considered an ideal tracer, owing 
to both its physical properties (low photon energy and 
a relatively long half-life) and its biochemical charac- 
teristics (it is not a parathyroid-specific tracer, but 
serves as an index of perfusion and cellular density) 
[2]. These drawbacks are accentuated by the closely ad- 
jacent thyroid tissue: since the thyroid is also a highly 
vascular and cellular gland, it takes up 2°IT1 avidly. For 
this reason subtraction techniques are utilized which ex- 
ploit the different biological behaviour and tissue dis- 
tribution of two tracers, namely the thyroid-specific 
99rrrFCO4- uptake relative to the more diffuse perfusion- 
dependent distribution of Z°ITI. A variety of different 
acquisition and subtraction protocols have been used 
[2-12] and this, together with the different patient popu- 
lations studied, probably explains the wide range of sen- 
sitivities reported (26%-94%) [13-15] (a positive cor- 
relation seems to exist between lesion size and its cor- 
rect scintigraphic localization) [10]. It is believed that 
the technique may be highly operator dependent and 
that there is a need for methodological modifications, 
particularly to standardize acquisition and processing 
protocols [16-18]. When optimized, the procedure 
generally has high sensitivity (75%-91%) [19]. In an 
attempt to improve the technique further, modifications 
of the acquisition or processing protocols continue to 
be proposed [16, 17]. The current role of scintigraphy 
in the localization of parathyroid enlargement remains 
the subject of considerable debate [20-23]. For these 
reasons there is significant interest in the development 
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of better tracers for parathyroid scintigraphy. Methoxy- 
isobutylisonitrile (MIBI), like 2°1T1, distributes primarily 
in proportion to tissue blood flow [24, 25] and was first 
introduced for the assessment of  myocardial  perfusion 
[24, 26, 27]. Being a technetium chelate, the new tracer 
will overcome the physical drawbacks of 2°1T1 and in 
1989 it was proposed for parathyroid scintigraphy [28]. 
99~Tc-MIBI/iodine-123 subtraction scintigraphy was 
demonstrated to be at least as accurate as 2°lTl/99nrFcO4- 
subtraction scintigraphy in localizing enlarged parathy- 
roid glands [29] and was also shown to display high 
sensitivity when imaging was performed at two time 
points. The early images after 99nTc-MIBI injection 
were taken as the thyroid phase and the late acquisition 
(2-3 h later) as the parathyroid phase [30]. 
The aim of this paper is to compare our results using 
99rrTc-MIBI/99rrTcO4- and 2°lTl/99rw['cO4- subtraction scin- 
tigraphy, ultrasonography and computed tomography 
(CT) in 43 patients operated on for hyperparathyroid- 
ism. 
Materials and methods 
One hundred and eight patients referred for suspected hyper- 
parathyroidism were entered into the study and underwent 
201T1/99mTcO4- and 99mTc-MIBI/99mTco4- subtraction scintigra- 
phy, ultrasonography and CT. In addition ten control subjects (two 
normal volunteers, five non-hyperparathyroid hypercalcaemic 
patients, two patients with multinodular goitres and one patient 
with a thyroid cyst) were studied similarly, except that CT was 
not performed. The 43 patients who have to date undergone sur- 
gical exploration and confirmation are the principal subject of 
this report. 
Scintigraphy was performed by means of a small field of view 
gamma camera (S.E.L.O., Italy), equipped with a parallel-hole, 
high-resolution collimator and a zoom factor of 1.5, on line with 
a microcomputer (Link System, UK). Data were recorded in 128 
x 128 word matrix. The following acquisition protocols were util- 
ized: 
2°JTl/99mTcO4-scintigraphy. 40 MBq of 99mTcO4- was adminis- 
tered by i.v, injection and was followed after 15 rain by dynamic 
acquisition of ten 60-s frames, using simultaneous dual-energy 
windows (20%) centered on the 80- and 140-keV photopeaks. 
Subsequently 80 MBq of 2°IT1 was injected i.v., and 5 rain later 
a similar dual-energy dynamic acquisition of 15 60-s frames was 
performed. 
99mTc-MIBI/99mTc04- scintigraphy. 40 MBq of 99mTco4- was ad- 
ministered by i.v. injection and was followed after 15 rain by 
dynamic acquisition of ten 60-s frames using a 20% window 
centered at the 140-keV photopeak. Subsequently 400-500 MBq 
of 99mTc-MIBI was injected i.v. and commencing 120 s later, a 
series of 20 60-s frames was acquired. 
Scans were read after normalizing the 20IT1 and 99mTc-MIBI 
images to the 99mTco4- images and subtraction was accomplished 
by choosing a correction factor which best adjusted the average 
counts in the thyroid area to the same level as that in surrounding 
tissues. This avoids false-negative results in cases of parathyroid 
adenomas lying within the thyroid region of interest. 
In 201Tl/99mTco4- subtraction scintigraphy the first image re- 
corded in the 80-keV peak, at the time when only 99mTcO4- had 
been administered, was used for scatter correction of 99mwc 
gamma rays into the 20IT1 k-x-ray emission window. 
Ultrasonography was performed scanning in the longitudinal 
and transverse planes, using a Hitachi 7.5-MHz linear probe. 
CT was performed using G.E, 9008 High Light equipment, 
acquiring 3-mm-thick slices in a 512 x 512 matrix before and 
after i.v. injection of 150-200 ml (flow rate of 2 mils) of a non- 
ionic contrast medium, Iopamidolo (Bracco, Italy), with an iodide 
concentration of 370 mg/ml. 
Results 
In normal volunteers and in patients with hypercal- 
caemia due to causes other than hyperparathyroidism, 
without palpable thyroid nodules, no mismatched areas 
of 2°iT1 or 99mTc-MIBl versus 99mTcO4- concentration 
were observed. 
In the presence of solid thyroid nodules, significant 
uptake of 2°1T1 and 99mTc-MIBI (generally higher than 
in the surrounding tissue) was observed whether or not 
the lesions showed uptake of 99rPr~cO4-. As expected, thy- 
roid cysts did not concentrate any tracer and neither did 
one almost exclusively cystic parathyroid lesion (see 
below). 
Of the 43 patients thus far operated on for hyper- 
parathyroidism, one was excluded from further analysis 
in this series because, despite secondary hyperparathy- 
roidism diagnosed on clinical and biochemical grounds, 
no localization was obtained by any of the four imaging 
modalities utilized, and furthermore surgical exploration 
did not reveal any site of parathyroid enlargement. 
Of  the remaining 42 patients, one had a large, almost 
exclusively cystic parathyroid adenoma, which, al- 
though located by both ultrasonography and CT, was 
interpreted as being a thyroid lesion (multinodular 
goitres being endemic in our area) and thus failed for 
parathyroid lesion location. 
2°lTl/99rrrFCO4- demonstrated the lesion(s) in 36 
patients (sensitivity 86%) while 99nTc-MIBI located the 
lesion(s) in 40 cases (sensitivity 95%). In 38 of them 
a single adenoma was present; one patient had two ad- 
enomas, and one had three. As the large majority of  
lesions were solitary, sensitivity was calculated for 
patients, interpreting a location to be correct only when 
all enlarged glands were correctly diagnosed. Although 
hyperplastic glands were localized in a few patients 
suffering f rom secondary hyperparathyroidism, they 
were not entered into this series as they have thus far 
not undergone surgery. 
Only two patients had a previous history of surgery 
for hyperparathyroidism; few conclusions can be drawn 
from such a small number. It is worth noting that in the 
detection of mediastinal adenomas, the sensitivity of  ul- 
trasonography dropped dramatically, as expected (0/4), 
but surprisingly the sensitivity of  CT was also low (1/4). 
In all but one of the cases, 99nTc-MIBI showed a 
qualitatively higher lesion-to-background ratio than 
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Table 1. 2°1T1 and 99mTc-MIBI uptake in 
thyroid and parathyroid, normalized for 
100 pixels and corrected for the pre- 
viously injected 99mTc04- contribution in 
the different areas in six patients with 
parathyroid adenomas which, being out- 
side the thyroid area, could be used to 
calculate uptake ratios 
Patient 2°1T1 99mTc-MIBI 
T P P/T T P P/T 
V.M. 4539 4802 1.058 13797 17959 1.302 
B.M. 3 141 3448 1.098 18 157 21625 1.191 
M.V. 3655 2941 0.805 36900 49333 1.337 
V.F. 2864 2860 0.999 10732 22262 2.074 
ED. 8918 7103 0.796 41541 63009 1.515 
G.P. 2390 1797 0.752 25958 31437 1.211 
0.918+0.151" 1.439_+0.332" 
(mean _+SD) (mean _+SD) 
T, Thyroid counts; P, parathyroid counts; P/T, parathyroid over thyroid uptake 
P=0.015 (two-tailed Student's t-test) 
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Fig. 1. a Patient EM. 
Top left: 99mTc-M1BI; top right: 
99ra TcO4_; bottom left: 99rnyc- 
MIBI- 99mTc04-. b Same patient 
as in a. Top left: 2mT1; top 
right: 99mTC04-; bottom left: 
2°1TI- 99mTC04-. The patient had 
a left inferior parathyroid ade- 
noma (arrows) 
Fig. 2. a Patient E.S. 
Top left: 99mTc-MIBI; top right: 
99mTco4-; bottom left: 99mTC- 
MIBI- 9~mTco4-. b Same patient 
as in a. Top left: 2°1T1; top 
right: 99mTco4-; bottom left: 
2°lTl- 99myco4-. Three parathy- 
roid adenomas - -  superior, infe- 
rior left and inferior right 
(arrows) - -  were present in this 
patient with tertiary hyper- 
parathyroidism 
2°IT1. This observa t ion  was objec t ive ly  conf i rmed  by re- 
gions of  interest  def ined over  the para thyroid  adenoma  
and adjacent  thyroid tissue in six patients (after correct-  
ing the 2°1T1 and 99~rrI'c-MIBI uptake  in the thyroid and 
para thyroid  areas for  the prev ious ly  injected 99myco4- 
and normal iz ing  counts for  100 pixels)  in w h o m  the 
adenomas  were  separate  f rom the thyroid tissue but did 
not lie in the medias t inum.  In these cases a higher  count  
rate should be  expec ted  for  the 99mTc chelate due to the 
higher  energy  photons  (Table 1). Statistical compar i son  
( two-tai led Student ' s  t-test) showed these differences to 
be significant  (P=0.015).  
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Fig. 3. a Patient DD. 
Top left: 99mTc-MIBI, top right: 
99mTc04-; bottom left: 99mTc- 
MIBI- 99mTco4-. b Same patient 
as in a. Top left: 2°1T1; top 
right: 99mTcO4-; bottom left: 
2°1T1- 99mTcO4-. This patient had 
a left superior parathyroid ade- 
noma (arrows) (size, 2 x 1 cm) 
The 99mTc-MIBI yielded images of clearly superior 
quality (Fig. 1) which allowed detection of the adenoma 
by visual inspection of the tracer distribution alone in 
34 of the 40 patients (85%) in whom 99rrrFc- 
MIBI/99nrFcO4 - subtraction scintigraphy correctly lo- 
cated lesions. In this group of patients the computer-as- 
sisted subtraction protocol merely confirmed the diag- 
nosis, while in the remaining six patients (15%) the le- 
sion could not be localized without this technique. In 
one patient with tertiary hyperparathyroidism and three 
enlarged parathyroids (0.8, 1.4 and 1.8 cm), 99nrFc- 
MIBI/99m'FcO4- subtraction scintigraphy was able to lo- 
cate all these tumours (Fig. 2a), while visual compari- 
son of 9 9 r m [ ' c - M I B I / 9 9 m T c O 4  - images and 2°tT1 scintigra- 
phy demonstrated only the largest lesion at the upper 
pole of the left thyroid lobe (Fig. 2b). 
Ultrasonography and CT correctly detected the le- 
sions in 34 and 35 patients (sensitivity 81% and 83%) 
respectively. One patient with secondary hyperparathy- 
roidism suspected on clinical and biochemical grounds 
was operated on although all four imaging modalities 
yielded negative results; no lesion could be found 
despite extensive surgical exploration. 
Discussion and conclusion 
The initial observation that the uptake of 99mTc-MIBI 
was enhanced in solid thyroid nodules could have been 
anticipated given the higher blood flow and cellularity 
which are frequently found in these lesions; confirma- 
tion in larger series is, however, needed. Thyroid-stimu- 
lating hormone control is known not to be a major fac- 
tor in 99~rrFc-MIBI uptake by thyroid tissue [27, 31]. 
Only one of our patients with thyroid nodules under- 
went surgery and in this patient a Htirthle cell carci- 
noma was found. This lesion corresponded to a focus 
of increased 99rrrFc-MIBI concentration as compared to 
normal surrounding tissue and 2°~T1 uptake was even 
greater. Unfortunately the imaging protocol did not in- 
clude early and delayed scans, so no comment can be 
made as to any possible difference in washout of 99mTc- 
MIBI from thyroid and parathyroid nodules [30]. While 
it has been reported that parathyroid lesions retain 99mTc- 
MIBI longer than thyroid tissue, it is worth noting that 
persistent uptake of the tracer 4 h after injection has 
been reported in a medullary thyroid carcinoma (al- 
though a more favourable tumour-to-background ratio 
was present in the early acquisition) [32]. A similar ob- 
servation has been made by Taillefer et al. in a case of 
follicular adenoma [30]. 
2°1T1 and 99"Tc-MIBI parathyroid scintigraphy, ultra- 
sonography and CT were all demonstrated to be reliable 
in locating parathyroid enlargement, with sensitivities 
ranging from 81% to 95%, scintigraphy being the most 
accurate modality. 2°tT1 and 991~Fc-MIB! scintigraphy 
gave relatively similar results and showed an excellent 
correlation, although the sensitivity of the new tracer 
was higher. Figure 3a is an example of a left superior 
parathyroid adenoma (size, 2 x 1 cm) correctly located 
by 99mTC-MIBI in spite of a negative 2°1T1 study (Fig. 
3b). In addition we wish to emphasize that more 
favourable uptake ratios for 99r'Tc-MIBI in parathyroid 
adenomas versus surrounding tissues were observed in 
all but one lesion (not included in Table 1 as it was 
located inside the thyroid region of interest). This lesion 
was made up exclusively of oxyphilic cells, which is 
an unusual histological pattern for parathyroid lesions. 
Unfortunately this does not improve our understanding 
of the exact mechanism of 99rrTc-MIBI uptake in para- 
thyroid adenomas, which seems to be a consequence of 
multifactorial influences including the biochemical 
properties of the tracer (lipophilicity and cationic 
charge) and local factors such as blood flow, transcapil- 
lary exchange, interstitial transport and negative intra- 
cellular charge of both mitochondria and membranes 
[25]. 
The high target-to-background ratio, together with 
the superior image quality due to the physical properties 
of 99rrr~C as a radiolabel, permitted the detection of ad- 
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enomas without any subtraction processing in a very 
large majority of the patients. This result might have 
been expected as a consequence of the favourable up- 
take ratio, the lesser degree of scatter and absorption of 
the 140-keV photons of 99nrFc and the higher count rates 
which are the consequence of the injection of larger 
activities of the 99n~c chelate. The latter could be 
achieved safely because the radiation dose to the patient 
has been demonstrated to be approximately 10-20 times 
less for 99n~Fc-MIBI than for 2°1T1 when the same activity 
is injected [28] (whole-body radiation doses for 
2°1T1=0.0555 mGy/MBq vs 0.0041 mGy/MBq for 99n~I'c- 
MIBI). These factors not only result in an improvement 
in sensitivity, but also make the scan easier to read and 
less operator dependent, which may contribute to more 
uniform and satisfactory diagnostic results. 
The subtraction of thyroid from parathyroid imaging 
which, when using 99~'1"cO4- and 2°1T1, may be readily 
performed as a consequence of photon emissions of 
different energies, was achieved by first injecting a 
small amount of 99nTcO4-, the distribution of which does 
not significantly interfere with the subsequent image of 
99~Fc-MIBI distribution which is obtained after injecting 
a much larger amount of the second 99"Fc-labelled tracer 
(ratio 10 or 12: 1). An alternative solution is that of 
Coakley and co-workers, who used ~23I as the tracer for 
thyroid mapping [28, 29]. ~23I is certainly ideal for thy- 
roid imaging due to its metabolic properties and the 
energy of its gamma emission; however, it is expensive 
and not always available. Finally, Taillefer et al. pro- 
posed a dual-phase scintigraphic technique after inject- 
ing 99~Tc-MIBI alone [30]. The initial image was con- 
sidered as the thyroid phase while the image obtained 
after 2-3 h was considered as the parathyroid phase due 
to the differential washout of normal thyroid tissue and 
enlarged parathyroid glands. This approach is interest- 
ing as it could avoid many of the drawbacks of sub- 
traction protocols. Nevertheless, a normal thyroid gland 
seems to be necessary because thyroid lesions may 
show altered 99n~c-MIBI clearance. In fact Taillefer et 
al. had a false-positive study in a patient with a follic- 
ular adenoma. A deeper knowledge of the mechanism 
of 99mTc-MIBI uptake and metabolism in various types 
of thyroid lesions is needed and Taillefer et al. suggest 
that the thyroid subtraction map should be obtained by 
means of another tracer in selected cases. We thus 
believe that such a technique may be suboptimal in geo- 
graphic areas where a significant incidence of thyroid 
nodules occurs (as is the case in our region). 
As a radiopharmaceutical 99~Tc-MIBI has the further 
advantage of always being available as a lyophilized 
MIBI kit which can be labelled in a single step. 2°~T1 
was first proposed for myocardial perfusion studies, and 
99~Tc-MIBI is also primarily used for this purpose. 
While the cost of 99myc for labelling is negligible, the 
lyophilized kit is expensive; however, because the che- 
late is very stable even when labelled with high activi- 
ties of 991VrFC, it is possible to obtain from one lyophil- 
ilzed vial sufficient tracer for either three or four cardiac 
studies and one parathyroid scintigraphic study. In these 
circumstances the cost falls below that of 2°~T1. 
Scintigraphy, ultrasonography and CT will continue 
to play a major role in localizing enlarged parathyroid 
glands. We were unable to compare the performance of 
magnetic resonance imaging (MRI) as i t  was not avail- 
able in our institution at the time. The role of this tech- 
nique, which has been used to a limited extent over the 
last 10 years to localize enlarged parathyroids [31-36], 
has still not been fully defined. MRI is certainly attrac- 
tive given its ability to permit imaging in the sagittal, 
coronal and transaxial planes, the lack of exposure to 
ionizing radiation, the excellent delineation of vascular 
structures without the need for contrast, the excellent 
spatial resolution and the fact that it enables some de- 
gree of in vivo tissue characterization. Nevertheless, 
MRI has not been shown to improve the localization of 
enlarged parathyroid glands significantly above that 
achieved by other techniques [33-36]. This, together 
with its high cost and somewhat limited availability, 
prevent MRI from being a routine screening test. 
We thus believe that 99r~c-MIBI is the new tracer of 
choice for parathyroid scintigraphy and foresee that it 
may gradually replace 2°1T1 for this indication in the 
majority of nuclear medicine units. 
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